Digital healthcare has gone through several investment routes: wearables in 2013, medical big data in 2014, virtual services in 2015, and investors have so far wanted to break the traditional medical payment landscape in 2016. It is expected that investment will return to the core of medical practice in 2017: technology. Technology can enable suppliers and biopharmaceuticals to expand their reach, but at the same time take a big risk. In 2016, the venture capital market focused on digital health startups that are breaking traditional industries. In the past 12 months, we have seen a large number of startups get financing, like the new company Bright Health received $80 million in April, and Clover Health's new medical advantage plan received $165 million in May, Collective Health The company's TPA/ASO replacement technology added $80 million in investment at the end of 2015. Hixme is an enterprise service company that encourages companies to give their employees the medical insurance benefits they pay for their employees, so that they can choose a medical treatment that better suits their situation. Type of insurance. Hixme and the new company Oscar will receive hundreds of millions of dollars in Series B and Series C financing. Why does this happen? Because taxpayers have always been an easy target. When the medical and medical reimbursement system covers a large area, a related operator will be born. They will build a huge network of suppliers and leveraged economies of scale and leasing to gain access to the employer's self-insurance network. In this case, the labor contract becomes less stable. With the help of Evolent Health, the vendor is risking the scale. Employers are building their own narrow network with the help of Imagine Health to control the volume of high-quality, low-cost centers. In this case, the medical loss rate is reducing the operator's profit. (The medical loss rate controls the proportion of operator premium income that needs to be spent on clinical services) In this regard, large operators respond to employer actions by merging or scaling up. However, seeking survival through mass and volume has its own limitations. Therefore, the US Department of Justice has intervened in anti-monopoly for Anthem to acquire Cigna for $54 million and Aetna to acquire Humana for $37 million. Breaking traditional medical payments Our view is that large-scale enterprises have labor and capital-intensive characteristics. In the United States, establishing links with 5,600 hospitals and 800,000 doctors is quite complex, such as issuing membership cards, verifying eligibility, processing claims, and attracting consumers to call when they call. Under this circumstance, it is difficult for investors to achieve the expected rate of return after the B round and C round of billions of investments. We have seen things like this: In 2013, investors invested tens of millions of dollars in Fitbit and Jawbone 2013 to develop wearable devices. In 2014, it was again to invest money in the use of medical big data to develop vertical applications such as “price transparencyâ€. This directly led to Castlight's controversial IPO. The investment in 2015 was all about telemedicine – Doctor on Demand IPO financing of $63 million, MDLive's IPO financing of $50 million, and Teladoc's IPO financing of $157 million. The news was announced in the eight-week window last summer. Later, investors in these financing events still did not get the reward they deserved when they quit. Strengthen immunity Is very important .Immunocompromised can suffer from a range of diseases, such as: susceptibility to infection by bacteria, viruses, fungi and other atypical pathogens such as mycoplasma and chlamydia, colds, upper respiratory tract infections, gastrointestinal infections, urinary Systemic infections, gastrointestinal infections.The main pharmaceutical raw materials for strengthening immunity are:Cyanoacetic acid,Chlorothalonil,Desloratadine,Tocopherol,Deoxyarbutin,Benzyloxyphenol,Tawanthin,Bithionol,Sulindac,Tocotrienols,Siponimod,Methylfolate,Minoxidil,Chlorophyl,Desonide,Propranolol,Tolnaftate,Ebastine,Amantadine Strengthen immunity Powder,Bulk Propranolol Powder,Tolnaftate Powder Xi'an Henrikang Biotech Co.,Ltd , https://www.xianhenrikangbio.com